[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=84ea3cd04ca1bb9484d096db8d85b2f9b7d1fff50cf5a6e3f8ce327fe90794c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751061003,
      "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 135614987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=84ea3cd04ca1bb9484d096db8d85b2f9b7d1fff50cf5a6e3f8ce327fe90794c5"
    }
  },
  {
    "ts": null,
    "headline": "Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care",
    "summary": "Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.",
    "url": "https://finnhub.io/api/news?id=4be894b084ecc152499725ef911940169b235906baaeedade785c7bc8aa1ad0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751055926,
      "headline": "Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care",
      "id": 135602310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.",
      "url": "https://finnhub.io/api/news?id=4be894b084ecc152499725ef911940169b235906baaeedade785c7bc8aa1ad0e"
    }
  },
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)",
    "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated risk evaluationand mitigation strategies , a safety program to protectpatients from risky drugs, for currently approved CAR-T...",
    "url": "https://finnhub.io/api/news?id=3508a599cbb68253c3338604d14ced1e2eca12c7796a604c1beffce76edbb0cf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751043568,
      "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)",
      "id": 135656836,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated risk evaluationand mitigation strategies , a safety program to protectpatients from risky drugs, for currently approved CAR-T...",
      "url": "https://finnhub.io/api/news?id=3508a599cbb68253c3338604d14ced1e2eca12c7796a604c1beffce76edbb0cf"
    }
  },
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies",
    "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated risk evaluationand mitigation strategies , a safety program to protectpatients from risky drugs, for currently approved CAR-T...",
    "url": "https://finnhub.io/api/news?id=735d4558ffc0b70e085a187d10142faf412a90a4ee63930428d2ab15b1a78136",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751043568,
      "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies",
      "id": 135598954,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated risk evaluationand mitigation strategies , a safety program to protectpatients from risky drugs, for currently approved CAR-T...",
      "url": "https://finnhub.io/api/news?id=735d4558ffc0b70e085a187d10142faf412a90a4ee63930428d2ab15b1a78136"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1fa16fdf084543701fe915c9fa3aacde1dc0180737e8e9783137016879740593",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751041800,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 135657205,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1fa16fdf084543701fe915c9fa3aacde1dc0180737e8e9783137016879740593"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Rises After Supreme Court Says Insurers Must Cover HIV Prevention Drugs",
    "summary": "Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.",
    "url": "https://finnhub.io/api/news?id=c1d79ad8fa6d55a37da7bb3c527d175b41f8c68a8298e17a713cdc0e7be7d135",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751037085,
      "headline": "Gilead Rises After Supreme Court Says Insurers Must Cover HIV Prevention Drugs",
      "id": 135591183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.",
      "url": "https://finnhub.io/api/news?id=c1d79ad8fa6d55a37da7bb3c527d175b41f8c68a8298e17a713cdc0e7be7d135"
    }
  },
  {
    "ts": null,
    "headline": "Kymera’s partnerships with Sanofi and Gilead drive value",
    "summary": "Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.",
    "url": "https://finnhub.io/api/news?id=65bbb6354bc508f445e9dd3bf2933a14dbf2fa6523bb749a00118284462e4ccd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751033969,
      "headline": "Kymera’s partnerships with Sanofi and Gilead drive value",
      "id": 135591184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.",
      "url": "https://finnhub.io/api/news?id=65bbb6354bc508f445e9dd3bf2933a14dbf2fa6523bb749a00118284462e4ccd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=774d891240fba23c0276b0543301a4119bf31b4fad7bd8c516c32e23a09f90fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751029204,
      "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 135591185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=774d891240fba23c0276b0543301a4119bf31b4fad7bd8c516c32e23a09f90fa"
    }
  },
  {
    "ts": null,
    "headline": "Debut Named to TIME's List of the TIME100 Most Influential Companies 2025",
    "summary": "Debut, the biotech beauty leader, was named to the TIME100 Most Influential Companies 2025. The annual list highlights 100 companies making an extraordinary impact around the world. Debut, named in the Innovators category and the first ever biotech beauty company to have made the list since its inception, stands alongside such companies as OpenAI, L'Oréal, Procter & Gamble, Waymo and Gilead.",
    "url": "https://finnhub.io/api/news?id=61fbd0dede7e54f9997f4f3b1ebc09e15283ff55a41f5cb2589c549c6a690a54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751029200,
      "headline": "Debut Named to TIME's List of the TIME100 Most Influential Companies 2025",
      "id": 135591186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Debut, the biotech beauty leader, was named to the TIME100 Most Influential Companies 2025. The annual list highlights 100 companies making an extraordinary impact around the world. Debut, named in the Innovators category and the first ever biotech beauty company to have made the list since its inception, stands alongside such companies as OpenAI, L'Oréal, Procter & Gamble, Waymo and Gilead.",
      "url": "https://finnhub.io/api/news?id=61fbd0dede7e54f9997f4f3b1ebc09e15283ff55a41f5cb2589c549c6a690a54"
    }
  },
  {
    "ts": null,
    "headline": "Gilead shares rise after US top court ruling on preventive coverage",
    "summary": "Shares of Gilead rose 3%after the U.S. Supreme Court on Friday upheld a federal mandatethat requires health insurers to cover preventive care servicesincluding those for reducing HIV risk and...",
    "url": "https://finnhub.io/api/news?id=38cc4f7bc30a90143a9243a6f48def3ccde0716c3ea4433280747618e8ec9050",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751024474,
      "headline": "Gilead shares rise after US top court ruling on preventive coverage",
      "id": 135592236,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Shares of Gilead rose 3%after the U.S. Supreme Court on Friday upheld a federal mandatethat requires health insurers to cover preventive care servicesincluding those for reducing HIV risk and...",
      "url": "https://finnhub.io/api/news?id=38cc4f7bc30a90143a9243a6f48def3ccde0716c3ea4433280747618e8ec9050"
    }
  },
  {
    "ts": null,
    "headline": "Gilead shares rise after US top court ruling on preventative coverage",
    "summary": "Shares of Gilead rose 3%after the U.S. Supreme Court on Friday upheld a federal mandatethat requires health insurers to cover preventive care servicesincluding HIV-preventing medication and cancer...",
    "url": "https://finnhub.io/api/news?id=e9146c75a03d0aefea16cb816116da4eba3fe034394b13004fd8f38a2e12fd5c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751024474,
      "headline": "Gilead shares rise after US top court ruling on preventative coverage",
      "id": 135591335,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Shares of Gilead rose 3%after the U.S. Supreme Court on Friday upheld a federal mandatethat requires health insurers to cover preventive care servicesincluding HIV-preventing medication and cancer...",
      "url": "https://finnhub.io/api/news?id=e9146c75a03d0aefea16cb816116da4eba3fe034394b13004fd8f38a2e12fd5c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead partners to advance novel oral oncology drug",
    "summary": "Gilead Sciences, Inc. and Kymera Therapeutics, Inc have agreed to jointly develop and commercialise a novel molecular glue degrader programme targeting cyclin-dependent kinase 2 for oncology...",
    "url": "https://finnhub.io/api/news?id=07d0f67cd45db7daa7eacf4bb0e395362f7d6c52bd4fba08a3ed2cd4f3160085",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751020266,
      "headline": "Gilead partners to advance novel oral oncology drug",
      "id": 135590865,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences, Inc. and Kymera Therapeutics, Inc have agreed to jointly develop and commercialise a novel molecular glue degrader programme targeting cyclin-dependent kinase 2 for oncology...",
      "url": "https://finnhub.io/api/news?id=07d0f67cd45db7daa7eacf4bb0e395362f7d6c52bd4fba08a3ed2cd4f3160085"
    }
  },
  {
    "ts": null,
    "headline": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD",
    "summary": "NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Gilead Sciences, Inc.  . Such investors are advised to contact Danielle Peyton at...",
    "url": "https://finnhub.io/api/news?id=399c7b54dbbbd05c3f211e3ecc2e4e9d0dacb24de9f7a822dc544ac16cfa601a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751018493,
      "headline": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD",
      "id": 135590692,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Gilead Sciences, Inc.  . Such investors are advised to contact Danielle Peyton at...",
      "url": "https://finnhub.io/api/news?id=399c7b54dbbbd05c3f211e3ecc2e4e9d0dacb24de9f7a822dc544ac16cfa601a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders",
    "summary": "FOSTER CITY, Calif. & WATERTOWN, Mass. - Gilead Sciences, Inc. and Kymera Therapeutics, Inc. , today announced that they have entered into an exclusive option and license agreement to accelerate the...",
    "url": "https://finnhub.io/api/news?id=c00f0828f1f83babbe8cee80fdea871e0a2f443b714fef4f019d78a4aa599a70",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751006469,
      "headline": "Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders",
      "id": 135588777,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY, Calif. & WATERTOWN, Mass. - Gilead Sciences, Inc. and Kymera Therapeutics, Inc. , today announced that they have entered into an exclusive option and license agreement to accelerate the...",
      "url": "https://finnhub.io/api/news?id=c00f0828f1f83babbe8cee80fdea871e0a2f443b714fef4f019d78a4aa599a70"
    }
  }
]